2025 Documentation Packaging 
FDA Law Blog: Biosimilars
FEBRUARY 2, 2025
By Sara M Keup In reviewing some new 2025 pharmacy rules/laws a couple interesting changes caught this bloggers attention: As of December 30, 2024, Missouri has rolled out new rules related to prescription drug delivery requirements. Massachusetts will begin enforcement against non-licensed pharmacy dispensing beginning on May 1, 2025.
Express Pharma
DECEMBER 30, 2024
He further highlighted the importance of thorough documentation, communication with regulators, and the need for a comprehensive understanding of the revised Schedule M guidelines. Looking ahead The next session in the PULSE series, focusing on Materials, Vendor Qualification and Reference Standards, is scheduled for January 5, 2025.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Express Pharma
MARCH 16, 2025
and Europe held manufacturers accountable for their environmental impact, leading to an increase in partnerships with tech companies focused on sustainable packaging and production solutions. What are the top 3 trends to watch out for in 2025,which could have a disproportionate impact on the globaland Indian life sciences landscape?
National Association of Boards of Pharmacy
OCTOBER 23, 2024
The exemption applies to “any … eligible trading partners, which … have successfully completed or made documented efforts to complete data connections with their immediate trading partners.” For wholesalers, these exemptions are granted until August 27, 2025. What requirements are dispensers actually exempt from?
Putting Patients First Blog
MARCH 18, 2024
Additionally, incorporating beneficiary feedback and pilot testing of revised Evidence of Coverage documents can ensure that MPPP information clarifies rather than complicates coverage understanding. For the Annual Notice of Change, accessible language that accommodates varied health literacy levels is vital.
Putting Patients First Blog
MARCH 18, 2024
Additionally, incorporating beneficiary feedback and pilot testing of revised Evidence of Coverage documents can ensure that MPPP information clarifies rather than complicates coverage understanding. For the Annual Notice of Change, accessible language that accommodates varied health literacy levels is vital.
PharmaShots
JUNE 1, 2023
These new results reinforce our differentiating data package for PDC*lung01. After the completion of the current clinical study with PDC*lung01 (PDC-LUNG-101), we plan to conduct a randomized, open-label phase 2 clinical trial with PDC*lung in the B2 cohort setting (2025 to 2028).
Expert insights. Personalized for you.
59 
Let's personalize your content